RenovoRx filed an amended 8-K to correct a hyperlink in its May 12, 2026 filing; no substantive changes were made. The underlying report disclosed second quarter 2026 financial results and raised full-year revenue guidance to $3.75 million–$4.25 million from $3.0 million–$4.0 million. Second-quarter revenue reached $909,000, a 61% sequential increase, with gross margin at approximately 84%. The company reported a net loss of $2.9 million and ended the quarter with $9.5 million in cash. Commercially, RenovoRx added five active cancer center customers to reach 21, while its Phase III TIGeR-PaC trial achieved full enrollment. RenovoRx operates in the life sciences industry, developing targeted oncology therapies and commercializing a drug-delivery device.

RenovoRx reported second quarter 2026 revenue of $909,000, a 61% sequential increase and 115% year-over-year growth. The company raised its full-year 2026 revenue guidance to $3.75 million–$4.25 million from the previous range of $3.0 million–$4.0 million. RenovoRx ended the quarter with 21 active commercial cancer center customers and announced the first treatment delivered with RenovoCath for sarcoma, expanding beyond pancreatic cancer. The Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in the second half of 2027. Net loss was approximately $2.9 million, and cash reserves stood at $9.5 million as of June 30, 2026. RenovoRx is a life-sciences company developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath drug-delivery device.

On July 1, 2026, RenovoRx, Inc. received notification from Nasdaq that it remains non-compliant with the $1.00 minimum bid price requirement. However, Nasdaq granted the company a second 180-calendar day compliance period, extending the deadline to regain compliance to December 28, 2026. To avoid delisting, the common stock must maintain a closing bid price of at least $1.00 for 10 consecutive business days. The company operates in the biotechnology industry and develops medical devices for drug delivery.

At its 2026 annual meeting on June 30, 2026, RenovoRx, Inc. stockholders approved an amendment to the Amended and Restated 2021 Omnibus Equity Incentive Plan to add 2,000,000 shares of common stock, representing 4.4% of total issued and outstanding shares, to the pool available for issuance. Stockholders also elected six directors for one-year terms and ratified the appointment of Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The company is a biotechnology firm that develops medical devices for the delivery of therapeutics.